Short Communication Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients

*both authors contributed equally to this manuscript Background. The 2009 pandemic of influenza A (H1N1) prompted an urgent worldwide vaccination campaign, es-pecially of high-risk subjects, such as maintenance haemo-dialysis (HD) patients. Still the immunogenicity of the pandemic A (H1N1) vaccine in HD patients is unknown. Methods. We prospectively studied the immunogenicity of a monovalent adjuvanted influenza A/California/2009 (H1N1) vaccine (Pandemrix, GSK Biologicals, Rixen-sart, Belgium) in HD patients and controls. Antibody level was measured using a seroneutralization assay before (D0) and 30 days after (D30) a single 3.75 lg vaccine dose. Specimens were tested in quadruplicates. Geometric mean (GM) antibody titers were determined in each subject at D